human
selling, general, and administrative expenses selling, general, and administrative expenses increased to $65.2 million in 2010 from $52.9 million in 2009 due primarily to increases in compensation expense and recruitment costs, principally in connection with higher headcount in 2010, and an increase in non-cash compensation expense for the reasons described above. cost of goods sold cost of goods sold in 2010 and 2009 was $2.1 million and $1.7 million, respectively, and consisted primarily of royalties and other period costs related to arcalyst ae commercial supplies. to date, arcalyst ae shipments to our customers have primarily consisted of supplies of inventory manufactured and expensed as research and development costs prior to fda approval in 2008; therefore, the costs of these supplies were not included in costs of goods sold. other income and expense investment income decreased to $2.1 million in 2010 from $4.5 million in 2009, due primarily to lower yields on, and lower average balances of, cash and marketable securities. interest expense increased to $9.1 million in 2010 from $2.3 million in 2009. interest expense is primarily attributable to the imputed interest portion of payments to our landlord, commencing in the third quarter of 2009, to lease newly constructed laboratory and office facilities in tarrytown, new york. income tax expense (benefit) in 2010, we did not recognize any income tax expense or benefit. in 2009, we recognized a $4.1 million income tax benefit, consisting primarily of (i) $2.7 million resulting from a provision in the worker, homeownership, and business assistance act of 2009 that allowed us to claim a refund of u.s. federal alternative minimum tax that we paid in 2008, and (ii) $0.7 million resulting from a provision in the american recovery and reinvestment act of 2009 that allowed us to claim a refund for a portion of our unused pre-2006 research tax credits. years ended december 31, 2009 and 2008 net loss regeneron reported a net loss of $67.8 million, or $0.85 per share (basic and diluted), for the year ended december 31, 2009, compared to a net loss of $79.1 million, or $1.00 per share (basic and diluted) for 2008. the decrease in our net loss in 2009 was principally due to higher collaboration revenue in connection with our antibody collaboration with sanofi-aventis, receipt of a $20.0 million substantive performance milestone payment in connection with our vegf trap-eye collaboration with bayer healthcare, and higher arcalyst ae sales, partly offset by higher research and development expenses, as detailed below. revenues revenues in 2009 and 2008 consist of the following:.
| (In millions) | 2009 | 2008 |
| --------- | --------- | --------- |
| Collaboration revenue |  |  |
| Sanofi-aventis | $247.2 | $154.0 |
| Bayer HealthCare | 67.3 | 31.2 |
| Total collaboration revenue | 314.5 | 185.2 |
| Technology licensing revenue | 40.0 | 40.0 |
| Net product sales | 18.4 | 6.3 |
| Contract research and other revenue | 6.4 | 7.0 |
| Total revenue | $379.3 | $238.5 |
.
Please answer the following question with expressions if necessary.
and what was that same percentage representation in 2009?
assistant
divide(67.3, 379.3)